Shohei Obayashi, Katsuyoshi Tomomatsu, Mika Urata, Jun Tanaka, Kyoko Niimi, Naoki Hayama, Tsuyoshi Oguma, Koichiro Asano, Yoko Ito
Internal medicine (Tokyo, Japan) 2022 May 15Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are common therapeutic agents for EGFR mutation-positive advanced non-small-cell lung cancer. There has been no report of rhabdomyolysis caused by an overdose of EGFR-TKIs. We herein review the existing literature on the subject and report a rare case of rhabdomyolysis due to an overdose of gefitinib, an EGFR-TKI.
Shohei Obayashi, Katsuyoshi Tomomatsu, Mika Urata, Jun Tanaka, Kyoko Niimi, Naoki Hayama, Tsuyoshi Oguma, Koichiro Asano, Yoko Ito. Rhabdomyolysis Caused by Gefitinib Overdose. Internal medicine (Tokyo, Japan). 2022 May 15;61(10):1577-1580
PMID: 34707044
View Full Text